Related Experiment Videos
Experience with isoxicam and catabolin
British Journal of Clinical Pharmacology
|January 1, 1986
Summary
This study investigated the impact of isoxicam on glycosaminoglycan (GAG) release in a cartilage model. Isoxicam demonstrated a potential to reduce cartilage resorption, suggesting it may not harm cartilage metabolism.
Area of Science:
- Biochemistry
- Pharmacology
- Cell Biology
Background:
- Synovial cells secrete catabolin, a protein factor that stimulates chondrocytes to resorb matrix and release glycosaminoglycan (GAG).
- Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used, but their effects on cartilage metabolism require thorough investigation.
Purpose of the Study:
- To evaluate the effect of isoxicam on GAG production in a catabolin-induced cartilage resorption system.
- To determine if isoxicam impacts inherent cartilage breakdown or catabolin-mediated GAG release.
Main Methods:
- A tissue culture system using bovine nasal septum was established.
- The system incorporated pooled porcine synovial tissue to generate catabolin.
- Isoxicam was added to the culture medium at varying concentrations (5-50 µg/mL) to assess its impact on GAG release.
Main Results:
- Inherent GAG release from cartilage breakdown was 49.7% after 8 days.
- Addition of synovial cells (catabolin) increased GAG release to 83.6%.
- Isoxicam (5-30 µg/mL) significantly reduced catabolin-induced GAG release to 70.9%; higher concentrations had no effect on inherent breakdown.
Conclusions:
- Isoxicam appears unlikely to impair cartilage metabolism.
- The NSAID may potentially decrease cartilage resorption mediated by catabolin.